Subsidiary of China Meheco Group (600056.SH) passes generic drug consistency evaluation.
Chinese medicine (600056.SH) announcement. Recently, the company's wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. (referred to as...
China Meheco Group (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd. ("Tianfang Pharmaceutical"), recently received a Drug Supplementary Application Approval Notice for tranexamic acid injection (referred to as "the drug") issued by the National Medical Products Administration. The drug passed the evaluation of generic drug quality and efficacy consistency. Tranexamic acid injection is mainly used for various types of bleeding caused by acute or chronic, localized or systemic primary fibrinolysis hyperfunction.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
